TEVA-LIOTHYRONINE TABLET

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Osta se nyt

Valmisteyhteenveto Valmisteyhteenveto (SPC)
20-11-2019

Aktiivinen ainesosa:

LIOTHYRONINE (LIOTHYRONINE SODIUM)

Saatavilla:

TEVA CANADA LIMITED

ATC-koodi:

H03AA02

INN (Kansainvälinen yleisnimi):

LIOTHYRONINE SODIUM

Annos:

5MCG

Lääkemuoto:

TABLET

Koostumus:

LIOTHYRONINE (LIOTHYRONINE SODIUM) 5MCG

Antoreitti:

ORAL

Kpl paketissa:

15G/50G

Prescription tyyppi:

Prescription

Terapeuttinen alue:

THYROID AGENTS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0102421001; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2019-11-21

Valmisteyhteenveto

                                _ _
_Teva-Liothyronine Tablets _
_Page 1 of 17_
PRODUCT MONOGRAPH
Pr
TEVA-LIOTHYRONINE
Liothyronine Sodium Tablets
5 mcg and 25 mcg liothyronine as liothyronine sodium
USP
Hypothyroidism Therapy
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Date of Approval:
November 20, 2019
Submission Control No: 217318
_ _
_Teva-Liothyronine Tablets _
_Page 2 of 17_
TABLE OF CONTENTS
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DRUG/LABORATORY TEST INTERACTIONS
.............................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION
............................................................................................................................12
CLINICAL PHARMACOLOGY
......................................................................................12
SUPPLY
.............................................................................................................................15
COMPOSITION
................................................................................................................15
PART III: CONSUMER INFORMATION
......................................................................16
_ _
_Teva-Liothyronine Tablets _
_Page 3 of 17_
Pr
TEVA-LIOTHYRONINE
liothyronine sodium
INDICATIONS AND CLINICAL USE
TEVA-LIOTHYRONINE is 
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Valmisteyhteenveto Valmisteyhteenveto ranska 20-11-2019

Etsi tähän tuotteeseen liittyviä ilmoituksia